ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

diacerein

Also written as “Diacerein”, “diacerein 1% ointment” and “AC-201”.

Its studies are mostly in Osteoarthritis, Knee · Epidermolysis Bullosa Simplex · Epidermolysis Bullosa · Psoriasis · Gout, led by 7 companies.

Drug pageDiacerein: every studyMany companies study it; this page follows only the 21 they lead. All 37 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 10, 201721 company-led studies, 2 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Castle Creek Pharmaceuticalsits history only70 open or runningphase 2since May 10, 2017May 10, 2017none ahead
TWi Biotechnologyits history only61 open or runningphase 3since Sep 12, 2023Jan 11, 2011none ahead
Wockhardtits history only30 open or runningphase 4since Feb 26, 2007Feb 26, 2007none ahead
TRB Chemedicaits history only21 open or runningphase 3since Mar 16, 2020Jun 28, 2010Dec 31, 2026phase 3 · NCT04318041
Accro Bioscience (Suzhou)its history only10 open or runningphase 2since May 7, 2025May 7, 2025none ahead
ANS Pharmaits history only10 open or runningphase 2since Jun 27, 2017Jun 27, 2017none ahead
TRB Chemedica International10 open or runningphase 3since Feb 10, 2016Feb 10, 2016none ahead

Also a collaborator on its studies: ArthroLab and TKL Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 10, 2016First study: phase 3 study in OsteoarthritisFirst studyNCT02688400 · 380 enrolled · Austria, Belgium, Canada and more

TargetBeta

IL1B →read by rule
“AC-203 (diacerein 1% ointment) is a topical formulation of diacerein, well-known for its ability to inhibit IL-1β and other proinflammatory cytokines.”study text, by rule · the study

Other programs on IL1B

ProgramCompanyFurthest phaseStudies
lutikizumabAbbViephase 312
arumakimigNovartisphase 27
ABBV-1451AbbViephase 11

Studies

The one study TRB Chemedica International leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02688400Osteoarthritis · Austria, Belgium, Canada and more3CompletedJun 26, 2018380

How it is read

Names in the registry

  • “Diacerein”, 4 entries
  • “diacerein 1% ointment”, 4 entries
  • “AC-201”, 3 entries
  • “AC-203”, 2 entries
  • “Diacerein 1% ointment”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.